A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
671
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
aliskiren
Sponsor
Novartis